Agile Therapeutics Profit Margin

The latest profit margin for AGRX is -73.52% as of June 2024. That compares with -262.03% in the prior-year period — up 71.9% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Agile Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, AGRX's profit margin moved from -262.03% to -73.52% — a 71.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Agile Therapeutics's valuation or profitability profile.

Against Healthcare companies, AGRX currently prints -73.52% for profit margin, while the sector average sits near 9.48%. That is roughly 875.5% below the sector mean. Large gaps often invite a closer look at Agile Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Agile Therapeutics converts resources into returns. At -73.52%, AGRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -262.03% in the prior-year period — up 71.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting AGRX's profit margin (-73.52%), review year-over-year change from -262.03%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.